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Background: Indices of left ventricular (LV) structure and geometry represent useful 
intermediate phenotypes related to LV hypertrophy (LVH), a predictor of cardiovascular 
(CV) disease (CVD) outcomes.
Methods and Results: We conducted an exome-wide association study of LV mass 
(LVM) adjusted to height2.7, LV internal diastolic dimension (LVIDD), and relative wall 
thickness (RWT) among 1,364 participants of African ancestry (AAs) in the Hypertension 
Genetic Epidemiology Network (HyperGEN). Both single-variant and gene-based sequence 
kernel association tests were performed to examine whether common and rare coding 
variants contribute to variation in echocardiographic traits in AAs. We then used a data-
driven procedure to prioritize and select genes for functional validation using a human 
induced pluripotent stem cell cardiomyocyte (hiPSC-CM) model. Three genes [myosin 
VIIA and Rab interacting protein (MYRIP), trafficking protein particle complex 11 
(TRAPPC11), and solute carrier family 27 member 6 (SLC27A6)] were prioritized based 
on statistical significance, variant functional annotations, gene expression in the hiPSC-CM 
model, and prior biological evidence and were subsequently knocked down in the 
hiPSC-CM model. Expression profiling of hypertrophic gene markers in the knockdowns 
suggested a decrease in hypertrophic expression profiles. MYRIP knockdowns showed 
a significant decrease in atrial natriuretic factor (NPPA) and brain natriuretic peptide (NPPB) 
expression. Knockdowns of the heart long chain fatty acid (FA) transporter SLC27A6 
resulted in downregulated caveolin 3 (CAV3) expression, which has been linked to 
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hypertrophic phenotypes in animal models. Finally, TRAPPC11 knockdown was linked to 
deficient calcium handling.
Conclusions: The three genes are biologically plausible candidates that provide new 
insight to hypertrophic pathways.
Keywords: exome sequencing, left ventricular hypertrophy, echocardiograph, cardiomyocyte model, hypertension, 
African-American
INTRODUCTION
Changes in left ventricular (LV) structure and geometry may 
evolve with myocardial injury or pressure overload and can lead 
to chamber dilation and/or hypertrophy (Gaasch and Zile, 2011). 
Echocardiography can identify such changes, while providing 
useful intermediate phenotypes predictive of cardiovascular (CV) 
disease (CVD) outcomes (Vasan et  al., 2009). Left ventricular 
mass (LVM), used clinically to define left ventricular hypertrophy 
(LVH), is an independent predictor of premature mortality across 
all genders, races, and ages (Casale et  al., 1986; Levy et  al., 1990; 
Gaasch and Zile, 2011). Additionally, increased LV wall thickness 
predicts CVD events (Vasan et al., 1997b), and LV dilation predicts 
heart failure (Vasan et  al., 1997a; Gardin et  al., 2006).
It is widely accepted that genetic factors influence LVM 
and other structural cardiac phenotypes. Heritability estimates 
for LVM (Sharma et al., 2006), LV internal diastolic dimension 
(LVIDD), and LV relative wall thickness (RWT) range between 
25 and 50% (Fox et  al., 2010; Jin et  al., 2011). Linkage (Arnett 
et  al., 2009a; Fox et  al., 2010), candidate gene association 
(Arnett et  al., 2009a; Lynch et  al., 2012), and genome-wide 
association studies (Arnett et  al., 2009b, 2011; Vasan et  al., 
2009) have reported loci suggestively or significantly associated 
with structural and functional echocardiographic traits.
Similar to the increased risk of hypertension and other 
CVDs, individuals of African ancestry (hereafter AAs) have 
greater average LV structural dimensions and other LV structural 
differences relative to individuals of European ancestry. LVH 
contributes more to the risk of CV mortality in AAs than it 
does in other ancestry groups (Havranek et  al., 2008). Also, 
AAs have a higher prevalence of concentric LVH characterized 
by an increased LVM and RWT (hypertrophic LV growth 
without overall chamber enlargement), which has a poorer 
prognosis and is usually the result of increased systolic pressure 
(Gaasch and Zile, 2011; Ahmad et  al., 2017). Overall, the 
extent to which genetic factors influence differences in LV 
phenotypes and the unique etiology of subclinical LVH in 
hypertension-prone AAs remain poorly understood.
We conducted a whole-exome association study of structural 
echocardiographic traits, including LVM adjusted to height2.7 
(LVM/Ht2.7), LVIDD, and RWT among AAs from the Hypertension 
Genetic Epidemiology Network (HyperGEN; Williams et  al., 
2000). Both single-variant and gene-based association tests were 
performed to examine the association between common and 
rare coding variants and echocardiographic traits in AAs. We sought 
functional validation of the association findings using a human 
induced pluripotent stem cell cardiomyocyte (hiPSC-CM) model.
MATERIALS AND METHODS
Study Population
Hypertension Genetic Epidemiology Network is one of the four 
networks in the National Heart, Lung and Blood Institute’s Family 
Blood Pressure Program, which aimed to identify genetic 
contributors to hypertension. As part of HyperGEN, hypertensive 
AA sibships were recruited from the community-at-large in 
Birmingham, AL, and population-based cohorts in Forsyth County, 
NC, from 1995 to 2000. Sibling pairs with onset of hypertension 
before age 60 years were recruited in the first phase. In a second 
phase, the study was extended to include other siblings as well 
as offspring of the hypertensive probands who were not being 
treated for hypertension. This study included 1,434 self-reported 
AA participants with relevant echocardiographic measurements 
and exome sequence data. The study was approved by the 
Institutional Review Boards of the participating organizations. 
All HyperGEN participants provided informed consent for use 
of samples and data for subsequent analyses.
Echocardiographic Data
Left ventricular traits were assessed by two-dimensional-guided 
M-mode echocardiography at the Birmingham, AL, and Forsyth 
County, NC field centers following a standardized imaging and 
reading protocol. All instruments were calibrated against a 
standard phantom at installation and were validated regularly 
(Tang et  al., 2002). Certificated sonographers from each center 
were trained at the echocardiography reading center at New York 
Hospital-Weill Cornell Medical Center where measurements were 
computerized, calibrated, and quantified using a review station 
with digitizing tablet and monitor overlay (Arnett et al., 2009a).
The study assessed LV structural phenotypes including LVM, 
LVIDD, and RWT. LVM was calculated with the following 
formula: LVM  =  0.8  ×  1.04  × [(IVS  +  LVIDD  +  PWT)3  − 
LVIDD3]  +  0.6  g, in which IVS is the interventricular septum 
thickness and PWT is the posterior wall thickness at end-diastole 
(in cm). IVS, PWT, and LVIDD were measured according to 
the American Society of Echocardiography recommendations 
(Devereux et  al., 1984a). LVM was further indexed to height 
in meters2.7. RWT was calculated as twice the PWT divided 
by the LVIDD (Devereux et  al., 1984b).
Exome Sequence Data
Exome sequencing was performed at the University of Washington 
(Auer et al., 2015). The processes of library construction, exome 
capture, sequencing, and mapping were performed as previously 
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described (Tennessen et al., 2012). Samples of DNA were quality 
controlled by concentration estimation by PicoGreen® (Thermo 
Fisher Scientific, Waltham, MA, United States). DNA samples 
were prepared by subjecting genomic DNA to shearing followed 
by ligation of sequencing adaptors. Exome capture for the 
samples was performed using the Roche Nimblegen SeqCap® 
EZ (Roche, Pleasanton, CA, United  States) according the 
manufacturer’s instructions. Paired-end sequencing (2 × 76 bp) 
was performed using GAII® and HiSeq® (Illumina, San Diego, 
CA, United States) sequencing instruments. For quality control 
(QC) purposes prior to release of sequence data, samples 
were initially converted from real-time base-calls to qseq.txt 
files using Illumina’s standard base caller, Bustard, and aligned 
to hg19 human reference using Burrows-Wheeler Aligner (Li 
and Durbin, 2010). Duplicate removal and insertion-deletion 
(INDEL) realignment were performed using the Genome 
Analysis ToolKit (GATK®, Broad Institute, Cambridge, MA; 
McKenna et  al., 2010). After using GATK filters, samples 
were required to reach at least 20x coverage over 70% of 
the exome target. Prior to release of individual-level sequence 
reads, sequence data were required to match known fingerprint 
genotypes for their respective samples.
Variant Calling Approach
All subjects were whole-exome sequenced at average mean read 
depth was 25. GATK’s best practice for calling germline variants 
is a multistep approach, which invokes the following GATK 
modules: (a) HaplotypeCaller module to generate per-sample, 
intermediate genomic variant call format (GVCF) files; (b) 
ImportGenomicsDB module to consolidate sample-level GVCF 
files; (c) GenotypeGVCF module to jointly call single-nucleotide 
polymorphisms (SNPs) and INDELs; and (d) VariantRecalibrator 
and ApplyRecalibration modules to retain high-quality variants 
and calibrate them to balance sensitivity and specificity. This 
multi-step approach produced a total of 642,878 variants across 
the 1,434 samples, which were further reduced to 528,450 variants 
with Variant Quality Score Log-Odds scores >0.99 derived from 
GATK’s Variant Quality Score Recalibration.
Sample Quality Control
To ensure retention of high-quality samples relevant to our 
research study, 1,434 genomic samples were reduced to 1,382 
through a quality-assurance pipeline that involved (a) removal 
of duplicate or twin sib pairs; (b) removal of blood sample 
mix-ups; and (c) removal of one non-AA sample through 
estimation of genetic principal components (PCs).
Additional quality assessment metrics were evaluated to 
retain high confidence samples and variants for downstream 
statistical analysis. After aligning the generated paired-end read 
sequences, the following QC steps were implemented: (a) total 
reads: exome completion typically requires a minimum of 30 M 
PE50 reads; (b) library complexity: the ratio of unique reads 
to total reads mapped to target (DNA libraries exhibiting low 
complexity are not cost-effective to finish); (c) capture efficiency: 
the ratio of reads mapped to human vs. the reads mapped to 
target; (d) coverage distribution: 90% at ≥8x required for 
completion; (e) capture uniformity; (f) raw error rates; (g) Ti/Tv 
ratio: typically 3.2 for known sites and 2.9 for novel sites 
(Wang et al., 2015); (h) distribution of known and novel variants 
relative to dbSNP (Ng et al., 2009); (i) fingerprint concordance 
>99%; (j) homozygosity; (k) heterozygosity; and (l) sample 
contamination validation. All QC metrics for both single-lane 
and merged data were reviewed by a sequencing analyst to 
identify data deviations from known or historical norms.
Variant Quality Control
To minimize false positives, only the following variants were 
retained: (a) genotyping quality >  20; (b) depth of coverage 
>  8; (c) bi-allelic variants (i.e., SNPs only); and (d) sample-
level genotype missing rate of < 10%. We included only autosomal 
SNPs. The above SNP-filtering criteria reduced the SNP space 
from 528,450 to 397,723, with 353,686 SNPs having a minor 
allele frequency (MAF) <  5%, of which 134,548 (38%) SNPs 
were singletons. The working set of 397,723 SNPs was further 
annotated using ANNOVAR and variants with MAF < 5% were 
classified into categories of replacement mutations [i.e., missense 
(nonsynonymous) and loss-of-function (stop-gain and stop-loss) 
mutations, see Supplementary Table S1]. Based on these 
annotations, a total of 202,697 were deemed probable deleterious 
and damaging variants: 199,104 missense mutations; 3,454 stop-
gain; and 139 stop-loss. ANNOVAR was used to capture 
functional prediction scores and classifications.
Statistical Analysis
A total 1,364 participants of 1,382 had genetic and 
echocardiographic data available for this analysis. Prior to 
performing genetic association tests, echocardiographic traits 
were transformed as needed to meet distributional assumptions 
(natural log transform of LVM/Ht2.7, LVIDD, and RWT). To 
address potential population stratification, we  performed PC 
analysis using EIGENSTRAT’s Smartpca module with variants 
with MAF  >  5%. The first 10 PCs were found to capture 
ancestral variation and hence were used as covariates in the 
downstream statistical analysis.
Genetic association was assessed at both the single-variant 
level [with minor allele count (MAC) >  5] as well as the gene 
level (no MAC filter) using RAREMETAL and 
RAREMETALWORKER (RMW; Liu et al., 2014), which reports 
results from gene-based tests including the Sequence Kernel 
Association Test (SKAT-RMW) which adjusts for family 
relationship. Since RMW does not include a function for joint 
testing of rare and common variants and our hypothesis centered 
around this combination of variants, we additionally implemented 
SKAT (Wu et  al., 2011) outside of the RMW framework, with 
a focus on the rare/common SKAT function (SKAT-RC; Ionita-
Laza et al., 2013). Models were adjusted for age, sex, recruitment 
center, and the top 10 PCs as fixed effects and kinship coefficients 
for sample relatedness within families (SKAT-RMW output 
only). In a sensitivity model, we additionally adjusted for body 
mass index [BMI, weight (kg)/height2 (m2)] and in a second 
sensitivity analysis we  adjusted for hypertension status. The 
Bonferroni-corrected significance thresholds for single variant 
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and gene-level tests were p  <  2.5  ×  10−7 (i.e., 0.05/202,697 
variants) and p < 3.01 × 10−6 (i.e., 0.05/16,579 genes), respectively. 
However, we  used a gene-based test p  <  1  ×  10−4 and other 
information to prioritize genes for cell model experiments (see 
Gene Selection section below).
hiPSC-CM Models
hiPSC-CM Cell Lines and Hypertrophy Model
We utilized iCell® Cardiomyocytes (iCell-CMs) from hiPSCs 
[Cellular Dynamics International (CDI), Madison, WI, 
United  States] to determine mRNA expression patterns; this 
particular line was derived from the fibroblast of a Caucasian 
female (<18  years old) using the retroviral transduction 
reprogramming method (Cellular Dynamics, 2020). These 
cardiomyocytes are a highly pure ventricular population having 
functional properties similar to adult human cardiomyocytes 
(Kattman et  al., 2011; Ma et  al., 2011). iCell-CMs were plated 
at 2.0  ×  104 cells/well in a 96-well plate pre-coated with 
fibronectin (5  μg/ml). After 10  days of recovery in iCell 
Maintenance Medium (CDI), the cells were cultured in William’s 
E medium supplemented with Cocktail B (1:25) from the 
Hepatocyte Maintenance Supplement Pack (Life Technologies 
Gibco®, Thermo Fisher Scientific) for an additional 4  days.
After a total of 14  days of culture, cells were harvested 
with Total RNA Purification 96-Well Kit (Norgen Biotek Corp, 
Thorold, ON, Canada). Total RNA was extracted per 
manufacturer’s recommendations, resuspended in nuclease-free 
water, and quantified by UV spectrophotometry (NanoDrop 2000, 
Thermo Fisher Scientific). Quality of total RNA was evaluated 
using total RNA Pico chip analysis on Agilent 2,100 Bioanalyzer 
(Agilent Technologies, Santa Clara, CA, United  States).
Illumina Hiseq Sequencing
We analyzed gene expression for the gene prioritization and 
selection analysis using RNA sequencing (RNA-seq). Paired-end 
cDNA libraries were prepared from 500  ng of total RNA from 
the iCell cardiomyocytes, using the TruSeq® RNA Sample 
Preparation Kit (Illumina). External RNA Controls Consortium 
(Baker et  al., 2005) reference materials were added to each 
RNA sample per manufacturer’s recommendations. Samples 
were sequenced on the Illumina HiSeq instrument following 
the manufacturer’s instructions. The samples were sequenced 
to a depth of at least 40 million paired-end reads per sample.
Gene Selection for hiPSC-CM Knockdown 
Experiments
Since all gene-based statistical tests include assumptions that 
may not perfectly fit the underlying genetic model, we prioritized 
genes for functional follow-up with a combination of criteria 
using a point-counting approach similar to that of previous 
work in HyperGEN (Zhi et  al., 2012). We  required genes to 
be: (1) associated with at least one structural trait (LVIDD, 
RWT or LVM/Ht2.7 with p < 1.0 × 10−4); (2) previously associated 
broadly with cardiovascular disease or metabolism in the literature; 
and (3) expressed in the hiPSC-CM model (see Illumina HISeq 
Sequencing section above) for a total of three points. The following 
four criteria were supportive: (1) association (p  <  0.05) with 
more than one of the structural traits, (2) harboring a loss of 
function variant, (3) previously linked to hypertrophy in the 
literature, and/or (4) having a mix of rare and common variants 
contributing to the gene-based statistic. To prioritize genes for 
functional validation analysis using knockdown experiments, 
we  summed the count of each criteria for a total of seven 
possible points and prioritized the gene selection by the total 
count. This procedure resulted in four genes with a prioritization 
score of 5. One of the four genes, prostaglandin E receptor 3 
(PTGER3), was not practical for knockdown in our model due 
to its role in cell signaling (i.e., PTGER3 is a prostaglandin 
receptor and cardiomyocytes do not produce prostaglandins).
Knockdown Experiments
Gene knockdown experiments were conducted in iCell-CMs using 
commercially available small interfering (si) RNAs (Thermo Fisher 
Scientific) targeting the identified candidate genes. hiPSC-CMs 
were plated in 96-well dishes at an approximate density of 1.71 × 104 
cells/well. Transfections were performed in triplicate using 
Invitrogen’s Lipofectamine® RNAiMAX reagent (Thermo Fisher 
Scientific) per manufacturer’s instructions. Each siRNA transfection 
was conducted using two unique Ambion® siRNAs (Thermo 
Fisher Scientific) per gene to ensure efficient gene knockdown. 
Invitrogen’s Block-iT™ fluorescent control (Thermo Fisher Scientific) 
was used as a positive control, with successful nuclear-localized 
fluorescence. Two negative controls were run with no discernable 
effect: (1) the transfection reagent without siRNAs and (2) Ambion® 
Silencer™ Negative Control No. 3 siRNA (Thermo Fisher Scientific). 
RNA extractions were performed with Norgen’s Total RNA 
purification 96-well kit (Norgen Biotek Corp). The knockdown 
efficiency was determined via real-time quantitative PCR (RT-qPCR) 
using TaqMan™ (Roche) gene expression assays following the 
manufacturer’s recommendations, normalizing to GAPDH, and 
compared to the Silencer Negative Control No. 3.
Targeted Whole-Transcriptome Sequencing
Targeted whole-transcriptome RNA sequencing was performed 
using the Ion AmpliSeq™ Transcriptome Human Gene Expression 
Kit (Thermo Fisher Scientific) on total RNA extracted from the 
iCell-CM knockdown experiments. Barcoded cDNA libraries 
were generated from 10 ng of total RNA, following manufacturer’s 
instructions. Quality of libraries was confirmed and quantification 
was done using Agilent Bioanalyzer High Sensitivity DNA Kit 
(Agilent Technologies). Sequencing was performed on the Ion 
Torrent™ Ion Proton™ sequencing platform (Thermo Fisher 
Scientific), using the Ion PI Hi-Q Sequencing 200 Kit. Three 
biological replicates were run for each condition.
Hypertrophic Gene Markers in siRNA Knockdown 
Experiments
Genes previously linked to hypertrophy, as reflected by an 
increase in LV wall thickness and/or LV dimensions, were 
selected to test for a hypertrophic expression profile in the 
knockdown cells (Carlson et  al., 2013). Differential gene 
expression analysis in knockdown experiments was performed 
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using the R/Bioconductor package DESeq2 (Love et  al., 2014). 
Only genes with median depth of ≥10 reads were considered. 
In particular, genes relevant to muscle contraction and regulation 
were evaluated, including actin genes [actin alpha cardiac muscle 
1 (ACTC1), actin alpha 1, skeletal muscle (ACTA1), actinin 
alpha 1 (ACTN1)]; mammalian heart myosin heavy chain genes 
[myosin heavy chain 6 (MYH6), myosin heavy chain 7 (MYH7)]; 
and the actin-binding protein gene transgelin (TAGLN; Warkman 
et  al., 2012; Despond and Dawson, 2018). A number of other 
markers were also evaluated. Natriuretic peptide A (NPPA) 
and natriuretic peptide B (NPPB) are evolutionarily conserved 
genes expressed by the heart during the embryonic and fetal 
stages. In adulthood, upon cardiac stress, NPPA and NPPB 
are upregulated in the ventricular myocardium (Man et  al., 
2018). Corin, serine peptidase (CORIN) is a cardiac serine 
protease that acts as a pro-atrial natriuretic peptide convertase 
(Wang et  al., 2008). F-box protein 32 (encoded by FBXO32, 
aliases MAFbx1, and ATROGIN1) is a cardiac and muscle 
specific F-box protein with E3 ligase activity that localizes at 
the sarcomere (Al-Yacoub et al., 2016). Tripartite motif containing 
63 (TRIM63) encodes muscle RING finger 1, which maintains 
muscle protein homeostasis by tagging the sarcomere proteins 
with ubiquitin for subsequent degradation by the ubiquitin-
proteasome system and imparts loss-of-function effects on E3 
ligase activity, which is causal for hypertrophy (Chen et  al., 
2012). Programmed cell death 4 (PDCD4) is upregulated during 
cardiomyocyte apoptosis and is involved in the inflammatory 
response and cellular differentiation (Jia et  al., 2016).
Ingenuity Pathway Analysis
We used Ingenuity Pathway Analysis (IPA, QIAGEN, Inc., 
https://www.ingenuity.com) software to analyze the differential 
mRNA expression gathered from the candidate gene knockdowns. 
Pathway analysis uses observed expression changes and combines 
these findings with predicted gene regulation and expression 
changes in associated network genes and gives different 
information than that provided by the knockdown models. 
Due to our focus on echocardiographic traits, we  selected 
cardiovascular pathways to analyze in depth. We  examined 
IPA’s canonical cardiovascular signaling pathways including 
cardiac hypertrophy signaling and cardiac beta-adrenergic 
signaling. Additionally, we  analyzed the pathway “Aldosterone 
signaling in epithelial cells.” Aldosterone has been recognized 
as being potentially hypertrophic (Yamamuro et  al., 2006; 
Messaoudi et al., 2013). We also analyzed the canonical toxicity 
pathways for mitochondrial function and NRF2-mediated stress 
responses. Finally, we  looked at metabolism changes since a 
switch from fatty acid (FA) metabolism to glucose metabolism 
in cardiomyocytes can be indicative of cardiomyopathy (Pascual 
and Coleman, 2016). This included IPA canonical pathways 
for FA beta-oxidation and PPARA/RXRA activation. Pathways 
could have either positive or negative z-scores for activation 
or repression of pathways, respectively. The reported z-score 
helps to infer the activation or repression of the implicated 
biological functions based on the relationship between the 
observed molecular network patterns and the derived effect 
based on the literature.
RESULTS
Study Population
Characteristics of the HyperGEN population are described in 
Table  1, which compares participants above and below the 
median value of LVM/Ht2.7 (note we dichotomized the phenotype 
for this table only; discovery genetic models were of continuous 
LV traits). On average, those with above-median LVM/Ht2.7 
were older, more likely male, had higher BMI, and were more 
likely to be  diabetic. This group also had higher values of 
other structural indices (RWT and LVIDD).
Single Variant Tests
There was no single variant with MAC > 5 that met the genome-
wide significance level threshold after correction for multiple 
testing (p  <  2.5  ×  10−7) for the three echocardiographic traits. 
Supplementary Figure S1 shows the QQ plots for single variant 
analysis with (a) no variant filter, (b) MAC  >  1 filter, and (c) 
MAC  >  5 filter. Three variants with MAC  >  5  in three different 
genes [regenerating family member 3 gamma (REG3G) for 
lnRWT, activating transcription factor 7 interacting protein 2 
(ATF7IP2) for lnLVIDD, and A-kinase anchoring protein 12 
(AKAP12) for lnLVIDD] approached statistical significance 
(Supplementary Table S2). As the majority of the borderline 
significant SNP findings were very rare (MAC  <  5), gene-based 
results became the focus of the analysis and were used to select 
genes to carry forward to functional cell-model assays.
Gene-Based Tests and Gene Prioritization
Table 2 includes the gene-based results limited to the three genes 
with the highest gene prioritization score (=5) selected for 
knockdown in the hiPSC-CM model [myosin VIIA and Rab 
interacting protein (MYRIP), trafficking protein particle complex 
11 (TRAPPC11), and solute carrier family 27 member 6 (SLC27A6)]. 
Each gene was associated with a structural trait (lnLVIDD), 
expressed in the hiPSC-CM model, and had SKAT-RC p < 1 × 10−4 
for a total of three votes. Adjusting for BMI and, separately, 
hypertension in the gene-based association test models did not 
TABLE 1 | Descriptive characteristics of the Hypertension Genetic Epidemiology 
Network (HyperGEN) African ancestry (AA) cohort.








Age (years) 49.1 (11.2) 48.0 (11.3) 50.2 (11.1) <0.001
Female (%) 877 (64.3) 512 (75.1) 365 (53.5) <0.0001
Field site 0.037
Alabama (%) 1,010 (74.0) 517 (75.8) 493 (72.3)
North Carolina (%) 315 (23.1) 140 (20.5) 175 (25.7)
Missing site data (%) 39 (2.9) 25 (3.7) 14 (2.0)
BMI (kg/m2) 32.0 (7.5) 29.9 (6.4) 34.1 (7.9) <0.0001
Diabetes (%) 294 (21.6) 120 (17.6) 174 (25.5) <0.001
LVM/Ht2.7 (g/m2.7) 43.6 (12.6) 35.2 (7.0) 51.9 (11.4) <0.0001
RWT 0.34 (0.05) 0.33 (0.05) 0.35 (0.06) <0.0001
LVIDD (cm) 5.2 (0.5) 4.8 (0.3) 5.5 (0.5) <0.0001
BMI, indicates body mass index; LVIDD, left ventricular internal dimension at diastole; LVM/
Ht2.7, left ventricular mass adjusted to height in meters2.7; and RWT, relative wall thickness.
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substantially change the results for the three genes. Each gene 
received two additional votes corresponding to supportive 
prioritization criteria. Single variant statistics for markers 
contributing to gene-based tests, gene expression data from the 
hiPSC-CM model, and fulfillment of gene prioritization categories 
are presented in the Supplementary Spreadsheet. For MYRIP, the 
two additional gene prioritization criteria were fulfilled by the 
contribution of both rare and common variants to the gene-based 
statistic (22 rare and two common) and that one of those variants 
was a rare loss of function variant (3:40085643, MAF  =  0.0004). 
The average MAF of the 22 rare variants was 0.002 and the two 
common variants (3:40223771 and 3:40275461) had MAF 0.23 
and 0.10, respectively. SLC27A6 had 13 variants (average rare 
variant MAF 0.006) contributing to the gene-based statistics, with 
one variant being common (5:128301885, MAF  =  0.21) fulfilling 
one additional prioritization criteria. The other criterion was met 
by an existing publication reporting a common (MAF  =  0.37) 
5’ UTR variant associated with LVH (Auinger et  al., 2012). In 
TRAPC11 both rare and common variants as well as a loss of 
function variant were observed fulfilling two prioritization criteria. 
The 22 rare variants had average MAF  =  0.005, including the 
loss of function variant (4:184633795) with MAF  =  0.0004.
Candidate Gene hiPSC-CM Knockdowns
Each of the three prioritized genes was successfully knocked 
down in the cell model using gene-specific siRNA. We  used 
RT-qPCR to show the efficiency of the knockdown procedures 
(Supplementary Figure S2) before performing target whole 
transcriptome sequencing. SLC27A6 proved the most efficient 
knockdown at 96.5%, while TRAPPC11 and MYRIP each showed 
significant expression reduction at 85.4 and 80.3%, respectively, 
compared to control cells transfected with Silencer Negative 
Control #3.
Cardiac Hypertrophy Markers
Expression profiling of hypertrophic gene markers in the 
hiPSC-CM knockdowns overall suggest a decrease in hypertrophic 
expression profiles (Figure 1). SLC27A6 and MYRIP knockdowns 
both showed significant decrease in the expression of actin 
genes ACTA1 and ACTC1. Knockdown of SLC27A6 and 
TRAPPC11 showed significant decreases in MYH7. MYRIP 
knockdowns showed a very significant decrease in NPPA and 
NPPB expression. TRAPPC11 knockdowns, however, showed 
a significant increase in NPPB expression. PDCD4 was highly 
upregulated in both SLC27A6 and MYRIP knockdowns.
Pathway Analysis of MYRIP Knockdowns
Differential expression analysis of MYRIP knockdowns compared 
to the control identified changes in expression of cardiac 
hypertrophy pathways. Both “Cardiac hypertrophy signaling” 
and the “Role of NFAT (nuclear factor activated T cells) in 
cardiac hypertrophy” pathways had significantly positive z-scores 
greater than +1 (+2.4 and +3.1, respectively) suggesting pathway 
activation (Figure  2) characterized by increased expression 
of receptors, intermediate signalers, and downstream 
hypertrophic effectors. The aldosterone-signaling pathway for 
the MYRIP knockdown model was also scored as significantly 
upregulated with a positive z-score of +2.3. Within this model 
(Supplementary Figure S3), there is a significant increase 
in expression of the aldosterone mineral corticoid receptor 
nuclear receptor subfamily 3 group C member 2 (NR3C2). 
Furthermore, within this pathway there is a significant increase 
in the expression of protein kinase C epsilon (PRKCE) and 
the Na+/H+ antiporter SLC9A1 when compared to control. 
Differential expression pathway analysis showed a significant 
decrease (z-score −5.2) in oxidative phosphorylation in MYRIP 
knockdowns. Over 70% of genes involved in the canonical 
oxidative phosphorylation pathway experienced a significant 
decrease in expression compared to the control, while only 
10% of genes were upregulated.
Pathway Analysis of SLC27A6 
Knockdowns
Differential expression of SLC27A6 knockdowns predicted 
significant upregulation of the “Cardiac hypertrophy signaling” 
and “Role of NFAT in cardiac hypertrophy” pathways (z-
scores +1.9 and +1.7, respectively; see Figure 2). Aldosterone 
signaling was also predicted to be upregulated (z-score +2.3) 
due to the significantly increased expression of PKC genes 
[like PRKCE and protein kinase D3 (PRKD3)] and mitogen 
TABLE 2 | Genes selected for functional follow up in human induced pluripotent stem cell cardiomyocyte (hiPSC-CM) models by prioritization scheme¶.
Trait Gene Total Vars Rare Avg MAF SKAT-RC* p SKAT-RC§ p SKAT-RC% p SKAT-RMW† p
lnLVIDD SLC27A6 13 10 0.006 3.37 × 10−6 2.58 × 10−7 8.10 × 10−6 3.38 × 10−6
lnLVIDD TRAPPC11 22 17 0.005 4.71 × 10−5 4.15 × 10−4 4.07 × 10−5 2.91 × 10−4
lnLVIDD MYRIP 24 21 0.002 3.93 × 10−5 2.86 × 10−5 8.11 × 10−6 5.14 × 10−3
Avg MAF indicates average minor allele frequency; LVIDD, left-ventricular internal diastolic dimension; SKAT-RC, sequence kernel test-rare/common function; SKAT-RMW, sequence 
kernel test-rare metal worker function; and Vars, variants. *Adjusted for age, sex, recruitment center, and 10 ancestry principal components (Pcs).
§Additionally adjusted for body mass index.
%Additionally adjusted for hypertension status.
†Corrected for family relationships.
¶Each gene was required to be associated with a structural trait [LVIDD, RWT, or left ventricular mass (LVM) adjusted to height in meters2.7] with p < 1 × 10−4, expressed in the hiPSC-
CM model, and broadly related to cardiovascular disease in the literature for a total of three points, additional points were accumulated for (1) Having a loss of function variant 
[myosin VIIA and Rab interacting protein (MYRIP), trafficking protein particle complex 11 (TRAPPC11)], (2) Reference related to hypertrophy solute carrier family 27 member 6 
(SLC27A6), (3) Having a mix of rare and common variants contribute to the gene-based statistic (MYRIP, SLC27A6, and TRAPPC11), or (4) Associated with more than one echo trait 
with p < 0.05 (not observed for top genes) for a possible total of seven points.
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activated protein kinase phosphatase 1 (MPK1). Of particular 
interest to the SLC27A6 knockdowns was the significant 
upregulation among all genes associated to cholesterol 
biosynthesis compared to the control. CAV3, which codes 
for the caveolin protein in myocytes, was significantly 
downregulated in the IPA pathway (Supplementary Figure S4) 
and consistently we observed significantly decreased expression 
of CAV3 in the SLC27A6 knockdown cardiomyocytes (value 
of p 1.64  ×  10−5), supporting a hypothesis of disrupted 
caveolae formation (Figure  3).
Pathway Analysis of TRAPPC11 
Knockdowns
Comparison of TRAPPC11 knockdowns to the control showed 
insignificant expression changes in canonical hypertrophic 
pathways (Figure 2). Cardiac β-adrenergic signaling was predicted 
to be downregulated with significant decrease in the expression 
of Na+/Ca2+ exchanger member SLC8A1 and the ryanodine 
receptor 2 (RYR2). Such a predicted decrease could lead to a 
deficiency in Ca2+ handling (Supplementary Figure S5). 
Furthermore, TRAPPC11 knockdowns showed more definitive 
pathway changes for peroxisome proliferator-activated receptor 
alpha/retinoid X receptor alpha (PPARA/RXRA) activation 
compared to MYRIP and SLC27A6. RXRA and some other 
downstream effectors had elevated expression leading to an 
overall predicted upregulation of this pathway.
DISCUSSION
Increased left ventricular dimensions are prognostic of a host 
of cardiovascular outcomes that overburden individuals of 
African Ancestry. Among AAs, hypertension is associated with 
abnormalities in left ventricular structure, including both 
concentric (increased LVM with increased RWT and normal 
or decreased LVIDD) and eccentric (increased LVM with 
increased LVIDD) forms of hypertrophy (Abdalla et  al., 2016). 
Heritability studies (Sharma et  al., 2006; Fox et  al., 2010; Jin 
et  al., 2011) as well as prior genome-wide association 
investigations (Arnett et  al., 2009b, 2011; Vasan et  al., 2009) 
suggest genes contribute to variability in these phenotypes. 
Previous studies have mostly focused on common genetic 
variation and identified markers that explain only a small 
portion of echocardiographic trait variation. We  undertook a 
whole-exome sequencing analysis of structural and functional 
echocardiographic traits in the AA participants of the HyperGEN 
study and used a data-driven gene prioritization procedure to 
select genes for validation in a hiPSC-CM model. Three genes 
were prioritized and successfully knocked down in the cells. 
Compared to control cells, knockdown cells showed altered 
expression of genes in cardiovascular pathways providing new 
insight into disease-relevant mechanisms.
MYRIP is a Rab effector protein, which facilitates melanosome 
transport and is detected in multiple tissues including the 
heart. It is also is involved in secretory vesicle transport, 
such as from the adrenal chromaffin cells (where catecholamines 
such as epinephrine, norepinephrine, and dopamine are 
produced and released systemically; Desnos et  al., 2003). In 
our study, MYRIP knockdown was associated with significantly 
decreased expression of NPPA and NPPB, 2 adjacent and 
highly conserved genes that have a complex relationship to 
hypertrophic phenotypes. In our cell models, a decreased 
expression appeared to be  protective for LVH. However, in 
the context of cardiac stress (e.g., cardiac ischemia), NPPA 
and NPPB expression increases in response to pressure overload-
induced hypertrophy in a compensatory response (Man et  al., 
2018). An inadequate response by these proteins may favor 
natriuresis and ventricular dilation (i.e., increased LVIDD; 
FIGURE 1 | Hypertrophic marker expression compared to control. Some 
hypertrophic genes experienced significant changes in expression in the 
knockdown model. False discovery rate (FDR), value of *p < 0.05, **p < 0.01, 
***p < 0.001, and ****p < 0.0001.
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Tamura et al., 2000; Man et al., 2018). MYRIP also significantly 
changed expression of actins (ACTA1 and ACTC1) and 
TAGLN, myocyte structural proteins. Variants in ACTC1 
have been associated with idiopathic dilated cardiomyopathy 
and familial hypertrophic cardiomyopathy (Augiere et  al., 
2015; Frustaci et  al., 2018). Differential expression analysis 
of MYRIP knockdowns compared to the control in IPA also 
showed changes in aldosterone signaling that included an 
increase in expression of the aldosterone mineral corticoid 
receptor, NR3C2. The mineral corticoid receptor is widely 
expressed in the cardiovascular system and is a major 
determinant of endothelial function, smooth muscle tone, 
vascular remodeling, and hypertension (Belden et  al., 2017). 
Individuals of AA are particularly prone to hypertension 
associated with primary aldosteronism (Zilbermint et  al., 
2019). A potential upregulation of this pathway further 
validates a role of MYRIP in left ventricular remodeling. 
Finally, based on gene expression, there was a very significant 
predicted decrease in the regulation of the oxidative 
phosphorylation pathway in MYRIP knockdowns, suggesting 
a state of relative energy deprivation characteristic of LVH 
and heart failure (Scolletta and Biagioli, 2010).
SLC27A6 encodes a member of the FA transport protein family 
(FATP6), the predominant FA transporter in the heart. In the 
healthy heart, ATP requirements are generally met by FA oxidation 
with smaller contributions from other sources (such as glucose, 
lactate, and branch-chain amino acids); increased reliance on 
non-FA fuels is characteristic of a “fetal program” of substrate 
metabolism typical of LVH (Neubauer, 2007; Tuunanen et  al., 
2008). SLC27A6 has also been linked to other CV-related outcomes 
in humans (Nielsen et  al., 2018; Roselli et  al., 2018; Van Der 
Harst and Verweij, 2018). With the knockdown of SLC27A6, IPA 
also predicted decreased expression of caveolin 3 (CAV3). This 
relationship was confirmed in our cell model. Caveolae are 
cholesterol- and sphingolipid-enriched membrane microdomains 
that contain caveolins, structural proteins that are involved in 
cell growth and hypertrophy by organizing receptors and signaling 
molecules (including G-protein coupled receptors and natriuretic 
peptide receptors; Horikawa et al., 2011). There are three caveolin 
isoforms, and previous research has shown Cav3 knockout mice 
show signs of muscle myopathic changes, cardiac hypertrophy, 
and cardiomyopathy (Woodman et  al., 2002). Upregulation of 
FIGURE 2 | Changes in expression profiles of pathways relevant to cardiac hypertrophy in candidate gene knockdowns. Orange (diagonal stripes, checkerboard), 
blue (dots, grid), and gray (triangles) colored boxes indicate significant changes in experimental pathway expression compared to the control (p ≤ 0.05). Dark blue 
(dots) indicates a significant negative z-score (≤−1) and a deactivation of the pathway, while dark orange (diagonal stripes) indicates a significant positive z-score (≥+1) and 
activation. Light colored (checkerboard, grid) and gray boxes indicate insignificant z-scores. White boxes marked with an X had insignificant pathway expression 
changes ( p ≥ 0.05).
FIGURE 3 | SLC27A6 knockdowns show a decreased expression of 
caveolin 3 (CAV3) compared to the control. A significant decrease in CAV3 
expression was noted in the SLC27A6 knockdowns. ****FDR p < 0.0001.
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Cav3 in a neonatal cardiac myocyte model reduced the ability 
of an adrenergic agonist (i.e., phenylephrine) and endothelin-1 
to provoke hypertrophy in that model (Koga et al., 2003). Another 
study showed that transgenic mice with cardiac myocyte-specific 
overexpression of Cav3 that were subjected to transverse aortic 
constriction had increased survival, reduced cardiac hypertrophy, 
and maintenance of cardiac function compared with control mice. 
Mutations in Cav3 have also been linked to the long QT type 
9 inherited arrhythmia syndrome (Tyan et al., 2019). As predicted 
by IPA as a consequence of SLC27A6 downregulation was SLC27A1 
(alias FATP1) upregulation, which may be  compensatory. In the 
heart, overexpression of SLC27A1 leads to LVH and LV diastolic 
dysfunction similar to that seen with diabetic cardiomyopathy (a 
consequence of high circulating FAs and the insulin-resistant heart 
unable to bring in glucose; Chiu et  al., 2005; Wu et  al., 2006). 
Overall, a downregulation of SLC27A6 may lead to downregulation 
of CAV3 and upregulation of SLC27A1, which is plausibly involved 
in ventricular remodeling. PDCD4, which was upregulated in the 
SLC27A6 knockdown, may be another signal of increased cardiac 
apoptosis that is associated with cardiac stress, resulting in an 
increase in LVIDD (i.e., eccentric LVH; Xiao et  al., 2016).
Transport protein particles (TRAPP) are parts of a multiprotein 
complex involved in endoplasmic reticulum-to-Golgi trafficking 
(Sacher et  al., 1998; Kim et  al., 2006; Scrivens et  al., 2011). 
It is ubiquitously expressed in humans, reflecting its important 
role in basic cellular functions. The TRAPPC11 protein 
participates in numerous interactions with other TRAPP complex 
components. Similar to SLC27A6, TRAPC11 knockdown was 
associated with fewer alterations in hypertrophic marker 
expression as compared to MYRIP. In IPA, a decrease in cardiac 
β-adrenergic signaling was linked to a decrease in the expression 
of the Na+/Ca2+ exchanger and RYR2, potentially leading to a 
deficiency in Ca2+ handling. Overall, a downregulation TRAPPC11 
supports a defect in the transport of secretory proteins, potentially 
involving Ca2+ that warrants further investigation.
This study leverages several strengths, including a whole-
exome association discovery analysis of echocardiographic traits 
in a population of well-characterized participants of AA. We used 
a combination of statistical analysis, publicly available 
bioinformatics data, and gene expression data from our control 
cell models to prioritize our top findings. This resulted in a 
novel list of genes for functional follow-up in hiPSC-CMs. 
Limitations included the inability to test specific variants or 
groups of variants identified in human exomes in the cell model, 
where instead we used whole-gene siRNA knockdown as a proxy 
for gene disruption due to identified variants. Additionally, human 
induced pluripotent stem cell derived cardiomyocytes are known 
to not fully replicate the maturity of human cardiac myocytes. 
However, in this study, we used the commercially available iCell 
cardiomyocytes for the knockdown experiments, which were 
developed to represent a highly pure population of cardiomyocytes. 
Prior research performed a detailed quantitative analysis of the 
electrophysiological properties of these cells demonstrating several 
properties characteristic of mature cardiac myocytes (Ma et  al., 
2011). Further, the genes were not replicated in an independent 
population due to the difficulty finding comparable whole exome 
data paired with echocardiography in AAs. Also, these findings 
represent genes discovered in a relatively healthy population 
and validated in a model of normal cardiomyocytes. Future 
studies are needed to determine a role for these genes in diseased 
individuals and cell models (or even additional in vivo models).
The current study discovered three novel candidates (MYRIP, 
SLC27A6, and TRAPPC11) associated with LV internal diastolic 
dimension in AAs from HyperGEN. The three genes were 
successfully knocked down in a hiPSC-CM model and markers 
of hypertrophy were compared between the knockdown and 
controls cells. Knockdown of each gene was associated with 
significant cellular changes that give new insight into left-ventricular 
remodeling. In particular, MYRIP was associated with cardiac 
hypertrophy signaling (e.g., NFAT pathway, NPPA, and NPPB) 
and aldosterone signaling. SLC27A6 is a fatty acid transporter 
and our knockdown of the gene led to changes in caveolin 
expression (CAV3) whose protein product has previously been 
linked to hypertrophic phenotypes in animal models. Finally, 
TRAPPC11 was linked to a deficiency in calcium handling and 
RYR2 expression. In summary, the three genes are biologically 
plausible candidates associated with left ventricular structure and 
metabolism according to the results of the knockdown experiments. 
Future functional studies that focus on specific variants under 
normal and stress conditions in the hiPSC-CM models are warranted.
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